Table 3 Degree of concordance among apoB, LDL-C, and non-HDL-C levels at baseline and study endpoint in the pooled treatment groups for the overall population and treatment subgroups defined by baseline TG < and ≥2.26 mmol/L
| Â | N | Concordance between apoB and LDL-C | N | Concordance between apoB and Non-HDL-C |
|---|---|---|---|---|
Weighted kappaa (95Â % CI) | Â | Weighted kappaa (95Â % CI) | ||
Baseline (i.e., drug-naïve patients) | ||||
Overall Population | ||||
All Treatments | 716 | 0.49 (0.44, 0.53) | 716 | 0.66 (0.62, 0.69) |
 TG <2.26 mmol/L | 599 | 0.52 (0.47, 0.56) | 599 | 0.63 (0.60, 0.67) |
 TG ≥2.26 mmol/L | 117 | 0.56 (0.46, 0.65) | 117 | 0.64 (0.56, 0.72) |
ERN/LRPT | 393 | 0.50 (0.45, 0.56) | 393 | 0.67 (0.63, 0.72) |
 TG <2.26 mmol/L | 320 | 0.54 (0.49, 0.60) | 320 | 0.65 (0.60, 0.70) |
 TG ≥2.26 mmol/L | 73 | 0.56 (0.44, 0.68) | 73 | 0.65 (0.56, 0.75) |
Placebo | 323 | 0.46 (0.40, 0.53) | 323 | 0.65 (0.60, 0.70) |
 TG <2.26 mmol/L | 279 | 0.50 (0.43, 0.57) | 279 | 0.64 (0.58, 0.69) |
 TG ≥2.26 mmol/L | 44 | 0.55 (0.39, 0.71) | 44 | 0.71 (0.56, 0.85) |
Endpoint (i.e., following randomized treatment) | ||||
Overall Population | ||||
All Treatments | 716 | 0.61 (0.57, 0.64) | 716 | 0.73 (0.70, 0.76) |
 TG <2.26 mmol/L | 599 | 0.64 (0.60, 0.68) | 599 | 0.73 (0.70, 0.76) |
 TG ≥2.26 mmol/L | 117 | 0.57 (0.47, 0.67) | 117 | 0.70 (0.63, 0.78) |
ERN/LRPT | 393 | 0.64 (0.60, 0.69) | 393 | 0.73 (0.69, 0.77) |
 TG <2.26 mmol/L | 320 | 0.66 (0.61, 0.71) | 320 | 0.72 (0.67, 0.76) |
 TG ≥2.26 mmol/L | 73 | 0.64 (0.54, 0.75) | 73 | 0.71 (0.60, 0.82) |
Placebo | 323 | 0.53 (0.46, 0.59) | 323 | 0.65 (0.60, 0.71) |
 TG <2.26 mmol/L | 279 | 0.55 (0.49, 0.62) | 279 | 0.66 (0.61, 0.72) |
 TG ≥2.26 mmol/L | 44 | 0.53 (0.38, 0.69) | 44 | 0.68 (0.56, 0.81) |